Project Grant HT94252411005
Award Date
11/1/24
Completion Date
10/31/27
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $783,191.00 to the Regents of the University of Minnesota to conduct in vivo gene therapy research for Fanconi anemia. The award period runs from September 1, 2025 to August 31, 2028. As a prominent land-grant research institution, the University of Minnesota leverages its extensive academic capabilities to support the program's objectives of...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,848,000.00 to the Regents of the University of Minnesota to conduct research on therapeutic targeting of aberrant mRNA polyadenylation in lethal prostate cancer. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical investigations in this critical medical domain. The...
The federal Project Grant award of $591,096.00, awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), supports research by the St. Vincent's Institute of Medical Research in Australia. The goal of the project is to prevent bone marrow failure in Fanconi anemia through inhibition of the FANCM gene. The award period runs from July 15, 2025 to July 14, 2028. The research aims to develop innovative gene correction techniques and explore...
This Project Grant award of $154,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Regents of the University of Minnesota to develop a dual-targeting G/D CAR-T cell therapy for the treatment of rhabdomyosarcoma. The award period runs from September 1, 2025 to August 31, 2027. The University of Minnesota, a prominent land-grant research institution, will leverage its extensive medical research capabilities to...
This federal Project Grant award for $1,399,812.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The grant is awarded to the Regents of the University of Minnesota to conduct research on outcomes and late effects in pediatric and adolescent germ cell tumor survivors. This funding will enable...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,618,500.00 to the Regents of the University of Minnesota to support research aimed at "Targeting eIF4F Complex-Driven Translation of Oncogenic mRNAs in CRPC". The 3-year award, which runs from June 1, 2025 to May 31, 2028, will fund advanced biomedical research focused on innovative solutions to transform healthcare for military service...
The Regents of the University of Minnesota was awarded a $1,202,776 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2027 to map elements of DNA architecture responsible for malignant transformation in craniospinal sarcoma. Through this award, the University of Minnesota will conduct biomedical research to identify medical solutions for battlefield...
The Department of the Army Medical Command awarded a $1,124,030 Project Grant to St. Vincent's Institute Of Medical Research in Australia to support research titled "IN VIVO DELIVERY OF PRECISE GENE CORRECTION FOR TREATMENT OF FANCONI ANEMIA" from July 1, 2022 through August 31, 2025. The award is being made under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research aimed at transforming healthcare for...
This federal Project Grant award of $614,150.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the Regents of the University of Minnesota to enhance the long-term persistence of Chimeric Antigen Receptor (CAR)-Natural Killer (NK) cells for treating solid tumors. The award period runs from July 1, 2025 to June 30, 2027. As a prominent land-grant research institution, the University of Minnesota has a strong track record of...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,243,750 Project Grant to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, to develop allogeneic, multiplex base-edited, dual-targeted gamma delta CAR-T cell therapies for the treatment of metastatic castration-resistant prostate cancer. This 3-year award, with a project period from Sep 30, 2024 to Sep 29, 2027, will...